XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 7 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Jul. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2022
Collaboration And Other Agreements [Line Items]              
Revenues $ 10,397 $ 41,734   $ 48,029 $ 78,842    
Deferred revenue, current 18,584     18,584     $ 9,988
Deferred revenue, net of current portion 64,260     64,260     59,480
I-Mab | I-Mab Biopharma Collaboration and License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment           $ 15,000  
Development and regulatory milestones recognized       5,000      
Revenues 0 3,800   0 4,500    
One Time Millstone Credit             $ 4,500
Incyte Corporation | RevenuesFromCMOAgreementsMember              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment     $ 10,000        
Revenues 4,500 $ 1,100   9,600 $ 5,100    
Deferred revenue 7,000     7,000      
Deferred revenue, current 6,400     6,400      
Deferred revenue, net of current portion $ 600     $ 600